taselisib
Jump to navigation
Jump to search
Indications
- treatment of PI3K mutation positive breast cancer in combination with hormonal therapy fulvestrant (Faslodex)
Adverse effects
- substantial toxicity may preclude use
Mechanism of action
- inhibits PI3K
More general terms
References
- ↑ Smith M. PI3K Inhibitor Has Mixed Results in Advanced Breast Cancer Modest progression benefit, but substantial side effects, with taselisib. MedPage Today. June 03, 2018 https://www.medpagetoday.com/meetingcoverage/asco/73239
Baselga J, et al Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. American Society of Clinical Oncology (ASCO) 2018; Abstract LBA1006.